48 results on '"Plante, Sylvain"'
Search Results
2. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial
3. A novel fiber-optic based 0.014 ' pressure wire: Designs of the OptoWire (TM), development phases, and the O-2 first-in-man results
4. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial
5. A novel fiber‐optic based 0.014″ pressure wire: Designs of the OptoWire ™, development phases, and theO 2 first‐in‐manresults
6. A novel fiber‐optic based 0.014″ pressure wire: Designs of the OptoWire™, development phases, and the O2 first‐in‐man results.
7. Prehospital diagnosis and triage of ST-elevation myocardial infarction by paramedics without advanced care training
8. Comparison of Bivalirudin Versus Heparin on Radial Artery Occlusion After Transradial Catheterization
9. ACE-DD genotype is associated with the occurrence of acute coronary syndrome in postmenopausal women
10. 14 FRANTIC MINUTES.
11. Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women
12. Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery
13. Acute complications of percutaneous transluminal coronary angioplasty for total occlusion
14. PTCA of chronically occluded coronary arteries
15. LONG-TERM SAFETY OF TICAGRELOR MONOTHERAPY IN PATIENTS UNDERGOING PCI FOR STABLE CORONARY ARTERY DISEASE IN THE GLOBAL LEADERS STUDY: IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
16. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
17. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vsaspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial
18. Risk Scores do Not Adjust for aggressive, evidence-based Changes in Percutaneous Coronary Intervention Practice Patterns
19. Symptoms of Disturbed Sleep Predict Major Adverse Cardiac Events After Percutaneous Coronary Intervention
20. Response to Letter Regarding Article, “The sPLA 2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial”
21. The sPLA 2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial
22. THE SPLA2 INHIBITION TO DECREASE ENZYME RELEASE AFTER PERCUTANEOUS CORONARY INTERVENTION (SPIDER-PCI) TRIAL.
23. Vehicle On-Board Diagnostics Added Values
24. The ACE-DD genotype is associated with endothelial dysfunction in postmenopausal women
25. Does Hormonal Status Influence the Clinical Presentation of Acute Coronary Syndromes in Women?
26. Transradial coronary brachytherapy with the Novoste beta‐rail system
27. Platelet GPIIb/IIIa receptor blockade reduces infarct size in a canine model of ischemia-reperfusion
28. Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis
29. Ischemia-Induced Action Potential Shortening is Blunted by d-Sotalol in a Pig Model of Reversible Myocardial Ischemia
30. Comparison of propafenone versus procainamide for the acute treatment of atrial fibrillation after cardiac surgery
31. Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina
32. Absence of Increased In-hospital Complications With Reused Balloon Catheters
33. Myocardial infarction patients in the 1990s—their risk factors, stratification and survival in Canada: The Canadian assessment of myocardial infarction (CAMI) study
34. CORONARY ARTERIOGRAPHY SHOULD NOT BE ROUTINELY USED POSTINFARCTION IN PATIENTS HAVING RECEIVED THROMBOLYTIC THERAPY
35. Reuse of balloon catheters for coronary angioplasty: A potential cost-saving strategy?
36. Porous balloon catheters for local delivery: Assessment of vascular damage in a rabbit iliac angioplasty model
37. Left Main Coronary Angioplasty: Assessment of a “Risk Score” to Predict Acute and Long‐Term Outcome
38. Acute complications of ptca for chronic total occlusion
39. Assessment of the “long sheath” technique for percutaneous aortic balloon valvuloplasty
40. Does Hormonal Status Influence the Clinical Presentation of Acute Coronary Syndromes in Women?
41. Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina Relation to myocardial contractility, intensity of exercise and the adenosine triphosphate–sensitive potassium channel
42. THE SPLA2 INHIBITION TO DECREASE ENZYME RELEASE AFTER PERCUTANEOUS CORONARY INTERVENTION (SPIDER-PCI) TRIAL
43. Reuse of PTCA catheters is not associated with increased in-hospital complications
44. A novel fiber-optic based 0.014″ pressure wire: Designs of the OptoWire™, development phases, and the O 2 first-in-man results.
45. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial.
46. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.
47. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
48. Thrombus formation on guide wires during routine PTCA procedures: a scanning electron microscopic evaluation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.